[11C]CS1P1 PET imaging correlates with cerebral small vessel disease and Alzheimer's disease burden, suggesting implications for early detection.
Motivation: This study investigates the use of [11C]CS1P1 PET imaging to assess neuroinflammation as an early biomarker of cerebral small vessel disease (cSVD) and Alzheimer's Disease (AD). Goal(s): The goal of this study is to assess whether [11C]CS1P1 uptake correlates with cSVD or AD burden. Approach: The overall approach of this study is a prospective cross-sectional analysis correlating [11C]CS1P1 to white matter hyperintensity (WMH) burden and PiB Centiloid. Results: Among 23 participants, results showed a correlation between WMH burden and [11C]CS1P1 PET uptake in both normal appearing white matter and gray matter, suggesting its utility in identifying high-risk areas for disease progression. Impact: [11C]CS1P1 PET could be a biomarker of early AD and cSVD. This imaging approach could guide the timely application of disease-modifying therapies and possibly enhancing treatment outcomes.
No takes yet. Share an insight, caveat, or question.
Orukari et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: